Clinic
West Side Health Care District
West Side Health Care District was paid $21.11M by Medicaid between Jan 2018 and Dec 2024, across 70 billing codes. Its largest line is T1015, a visit at a community health center or clinic (one all-in rate) — 73% of everything it billed.
33Billing provider infoWEST SIDE HEALTH CARE DISTRICT
TAFT, CA 93268
TAFT, CA 93268
33aNPI1992142277assigned 05/28/2013
33bProvider typeUrgent Care Clinic/Center
28Total paid$21.11M
24GClaims391,146
24DCodes billed70
24AFirst – last monthJan 2018 – Dec 2024
Compared with peers
Next to other Urgent Care Clinic/Center providers in California
Rank by total paid#9 of 284
Median peer was paid$147K
This provider vs. median143×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 25,263 | $1.34M | |
| 2019 | 29,397 | $1.76M | |
| 2020 | 31,404 | $1.75M | |
| 2021 | 49,454 | $2.84M | |
| 2022 | 56,202 | $3.59M | |
| 2023 | 119,819 | $4.26M | |
| 2024incomplete | 79,607 | $5.58M |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| T1015 | A visit at a community health center or clinic (one all-in rate)Clinic visit/encounter, all-inclusive | 73% | 92,406 | 83,559 | $15.45M |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 15% | 118,366 | 70,041 | $3.14M |
| 99214 | Doctor's office visit, returning patient (more involved)Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity | 4.3% | 25,133 | 14,280 | $912K |
| G9008 | Coordinated care fee, physician coordinated care oversight services | 2.6% | 4,943 | 2,942 | $544K |
| 87428 | 2.2% | 19,307 | 11,111 | $463K | |
| 71046 | Radiologic examination, chest; 2 views | <1% | 7,088 | 4,931 | $96K |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | <1% | 4,726 | 3,004 | $76K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 5,810 | 3,018 | $68K |
| 98940 | <1% | 2,386 | 947 | $63K | |
| 99203 | Doctor's office visit, new patient (routine)Office or other outpatient visit for the evaluation and management of a new patient, low complexity | <1% | 1,063 | 873 | $61K |
| G9012 | Other specified case management service not elsewhere classified | <1% | 877 | 638 | $31K |
| 99395 | Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years | <1% | 461 | 263 | $28K |
58 more codes
| 93000 | <1% | 1,047 | $19K | |
| 99396 | Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years | <1% | 279 | $18K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | <1% | 4,201 | $15K |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 5,340 | $14K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 3,195 | $13K |
| 81003 | <1% | 11,370 | $9K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | <1% | 1,172 | $9K |
| 92551 | <1% | 1,251 | $9K | |
| 99394 | Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) | <1% | 172 | $8K |
| 81025 | <1% | 4,750 | $7K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 583 | $6K |
| 99215 | Doctor's office visit, returning patient (complex) | <1% | 166 | $5K |
| 87807 | <1% | 1,113 | $5K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 1,159 | $4K |
| 99393 | Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) | <1% | 88 | $3K |
| 96127 | <1% | 1,995 | $3K | |
| 99173 | <1% | 1,184 | $3K | |
| 90686 | <1% | 281 | $2K | |
| 99392 | Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) | <1% | 106 | $2K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 1,039 | $2K |
| 90656 | <1% | 185 | $2K | |
| 71020 | <1% | 75 | $2K | |
| 99202 | Office or other outpatient visit for the evaluation and management of a new patient, straightforward | <1% | 56 | $2K |
| 98941 | Chiropractic manipulative treatment; spinal, 3-4 regions | <1% | 158 | $2K |
| 73562 | <1% | 95 | $2K | |
| 90715 | <1% | 64 | $1K | |
| 74018 | <1% | 79 | $1K | |
| 73630 | <1% | 26 | $610.32 | |
| 82947 | <1% | 386 | $558.79 | |
| 83036 | Hemoglobin; glycosylated (A1C) | <1% | 133 | $533.75 |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 57 | $517.45 |
| 3008F | <1% | 17,406 | $438.83 | |
| 72100 | <1% | 12 | $381.60 | |
| 97032 | <1% | 630 | $357.39 | |
| 73130 | <1% | 14 | $237.60 | |
| 99188 | <1% | 54 | $237.60 | |
| 90460 | Immunization administration through 18 years of age via any route, first or only component | <1% | 609 | $208.28 |
| 85018 | <1% | 273 | $205.76 | |
| 71045 | Radiologic examination, chest; single view | <1% | 39 | $185.50 |
| 3079F | <1% | 6,403 | $182.27 | |
| 3078F | <1% | 10,626 | $182.25 | |
| 3077F | <1% | 3,694 | $148.17 | |
| 3074F | <1% | 12,621 | $120.48 | |
| 90461 | <1% | 87 | $109.33 | |
| 90471 | Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine | <1% | 138 | $9.36 |
| J7613 | Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg | <1% | 221 | $7.59 |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 536 | $0.04 |
| 1160F | 0% | 3,704 | $0.00 | |
| 1159F | 0% | 3,705 | $0.00 | |
| 3080F | 0% | 2,016 | $0.00 | |
| 3075F | 0% | 2,998 | $0.00 | |
| 36416 | 0% | 111 | $0.00 | |
| J7644 | Ipratropium bromide, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose form, per milligram | 0% | 88 | $0.00 |
| 1036F | 0% | 451 | $0.00 | |
| 1126F | 0% | 84 | $0.00 | |
| J7620 | Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme | 0% | 50 | $0.00 |
| 1125F | 0% | 125 | $0.00 | |
| 1034F | 0% | 80 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialSHULTZ, RYAN (EXECUTIVE DIRECTOR)